Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) Overview 6 Therapeutics Development 7 Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Stage of Development 7 Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Therapy Area 8 Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Indication 9 Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Products Glance 10 Early Stage Products 10 Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Companies 11 Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Universities/Institutes 13 Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 18 Assessment by Molecule Type 19 Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Companies Involved in Therapeutics Development 21 Apogenix GmbH 21 BioInvent International AB 22 Pfizer Inc. 23 Pieris Pharmaceuticals, Inc. 24 Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Drug Profiles 25 Aptamer to Antagonize CD137 for Oncology - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Monoclonal Antibodies to Agonize 41BB for Oncology - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 PRS-342 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 PRS-343 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Recombinant Protein to Agonize CD137 for Solid Tumor - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Ultra-41BBL - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 utomilumab - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Dormant Projects 34 Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Featured News & Press Releases 35 Mar 17, 2016: Pieris Pharmaceuticals Announces Presentation of In Vivo Preclinical Data for Its Lead Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) 35 Nov 06, 2015: Pieris Pharmaceuticals Presents Data at SITC Conference on Lead Immuno-Oncology Program Demonstrating Selective Tumor-Targeted Immune Responses 35 Sep 21, 2015: Pieris Pharmaceuticals Presents Positive Preclinical Data on Lead Bispecific Immuno-Oncology Program 36 May 13, 2015: MorphoSys To Present Data On PF-05082566 at American Society of Clinical Oncology Annual Meeting 36 Dec 22, 2014: MorphoSys Announces Clinical Milestone in Oncology Program 37 Dec 22, 2003: MorphoSys Forges Therapeutic Antibody Collaboration With Pfizer 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39

List of Tables Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by Apogenix GmbH, H1 2016 21 Pipeline by BioInvent International AB, H1 2016 22 Pipeline by Pfizer Inc., H1 2016 23 Pipeline by Pieris Pharmaceuticals, Inc., H1 2016 24 Dormant Projects, H1 2016 34List of Figures Number of Products under Development for, H1 2016 7 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Mechanism of Actions, H1 2016 16 Number of Products by Stage and Mechanism of Actions, H1 2016 16 Number of Products by Molecule Types, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 19

Apogenix GmbH BioInvent International AB Pfizer Inc. Pieris Pharmaceuticals, Inc.